AI assistant
X4 Pharmaceuticals, Inc — Director's Dealing 2017
Nov 15, 2017
34355_dirs_2017-11-15_f01ee62f-d843-48e9-8d87-85ca1b3ea74b.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Arsanis, Inc. (ASNS)
CIK: 0001501697
Period of Report: 2017-11-15
Reporting Person: Russo Rene (Director, See Remarks, 10% Owner)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (right to buy) | $8.20 | 2025-07-21 | Common Stock (80889) | Direct | |
| Stock Option (right to buy) | $9.39 | 2026-07-19 | Common Stock (47757) | Direct | |
| Stock Option (right to buy) | $4.00 | 2027-06-18 | Common Stock (195331) | Direct |
Footnotes
F1: This option was granted on July 22, 2015 and vests over four years, with 25% of the original 80,889 shares underlying the option having vested on July 22, 2016, and 2.0833% of the original 80,889 shares vesting monthly thereafter, subject to continued service.
F2: This option was granted on July 20, 2016 and vests over four years, with 25% of the original 47,757 shares underlying the option having vested on July 20, 2017, and 2.0833% of the original 47,757 shares vesting monthly thereafter, subject to continued service.
F3: This option was granted on June 19, 2017 and vests over four years, with 25% of the original 195,331 shares underlying the option vesting on June 19, 2018, and 2.0833% of the original 195,331 shares vesting monthly thereafter, subject to continued service.